Core Viewpoint - Sino Medical Sciences Technology Inc. reported significant growth in revenue and net profit for the first half of 2025, driven by increased sales in its coronary and neuro-interventional product lines, reflecting the company's strong market position and innovation capabilities [2][3][15]. Company Overview and Financial Indicators - Sino Medical is focused on high-end interventional medical devices, with a comprehensive R&D, production, and operational system established over more than a decade [7][14]. - The company achieved a revenue of CNY 240.48 million in the first half of 2025, a year-on-year increase of 12.53% [2][15]. - The net profit attributable to shareholders reached CNY 13.84 million, marking a substantial increase of 296.54% compared to the same period last year [2][15]. - The company's total assets stood at CNY 1.31 billion, with net assets of CNY 894 million at the end of the reporting period [2][15]. Industry Context - The interventional medical device industry in China is experiencing robust growth, supported by government policies aimed at promoting high-end medical equipment development [5][6]. - The coronary intervention market has matured significantly, with a reported 26.44% increase in coronary intervention cases in 2023, indicating strong demand for innovative treatment options [6]. - The neuro-interventional sector is rapidly developing, with increasing domestic innovation and a growing market for neuro-interventional products [6][8]. Product and Innovation - Sino Medical's product portfolio includes leading coronary drug-eluting stents and neuro-interventional devices, with over 2.45 million units used across nearly 4,000 hospitals [8][14]. - The company has maintained a strong focus on R&D, with a total investment of CNY 77.81 million in the first half of 2025, representing 32.36% of its revenue [15]. - The company holds 145 authorized invention patents globally, reflecting its commitment to innovation and technological advancement [15].

Core Viewpoint - Sino Medical Science and Technology Co., Ltd. reported a significant increase in revenue and net profit for the first half of 2025, indicating a positive trend in its financial performance [1][3]. Financial Summary - Total assets at the end of the reporting period reached approximately 1.31 billion RMB, a 0.70% increase from the previous year [3]. - Revenue for the reporting period was approximately 240.48 million RMB, reflecting a 12.53% increase compared to the same period last year [3]. - The total profit amounted to approximately 23.01 million RMB, a significant recovery from a loss of approximately 4.74 million RMB in the previous year [3]. - Net profit attributable to shareholders was approximately 13.84 million RMB, a substantial increase of 296.54% compared to 3.49 million RMB in the same period last year [3]. - The net cash flow from operating activities was approximately 52.45 million RMB, a 303.38% increase from 13.00 million RMB in the previous year [3]. Shareholder Information - The total number of shareholders at the end of the reporting period was 11,090 [4]. - The top shareholder, Tianjin Weixin Sunshine Enterprise Management Consulting Co., Ltd., holds 5.47% of the shares [4]. - Other significant shareholders include Huang Songlang with 2.62% and Tianjin Sunshine Guangye Enterprise Management with 2.55% [4]. Profitability Metrics - The weighted average return on equity increased to 1.58%, up by 1.16 percentage points from 0.42% [4]. - Basic and diluted earnings per share were both reported at 0.03 RMB, an increase of 200% from 0.01 RMB [4]. Research and Development - The proportion of R&D investment relative to revenue was 32.36%, a decrease of 10.80 percentage points from 43.16% in the previous year [4].

证券代码：688108 证券简称：赛诺医疗 公告编号：2025-036 赛诺医疗科学技术股份有限公司 的议案" 经与会董事审议，一致通过"关于赛诺医疗科学技术股份有限公司 2025 年半年 度报告及其摘要的议案"。同意公司编制的《2025 年半年度报告》及其摘要。 具体内容详见公司于同日披露在上海证券交易所网站（www.sse.com.cn）的《赛 诺医疗科学技术股份有限公司 2025 年半年度报告》及《赛诺医疗科学技术股份有限 公司 2025 年半年度报告摘要》。 表决结果：同意 9 票；反对 0 票；弃权 0 票 特此公告。 赛诺医疗科学技术股份有限公司董事会 关于第三届董事会第六次会议决议的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 赛诺医疗科学技术股份有限公司（以下简称"赛诺医疗"或"公司"）第三届董 事会第六次会议通知于 2025 年 8 月 8 日以书面等方式送达各位董事和监事。会议于 厦 7 层公司会议室召开。本次会议应出席董事 9 人，实际出席董事 9 人。本次会议由 为定 ...

证券代码：688108 证券简称：赛诺医疗 公告编号：2025-037 赛诺医疗科学技术股份有限公司 关于第三届监事会第三次会议决议的公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 赛诺医疗科学技术股份有限公司（以下简称"赛诺医疗"或"公司"）第三届监 事会第六次会议通知于 2025 年 8 月 8 日以书面送达等方式通知各位监事。会议于 2025 年 8 月 21 日在北京市海淀区高梁桥斜街 59 号中坤大厦 7 层公司会议室以现场和通讯 相结合的方式召开。本次会议应出席监事 3 人，实际出席监事 3 人。本次会议由监事 会主席于长春先生召集并主持，公司部分高管列席了本次会议。本次会议的召开符合 《中华人民共和国公司法》等有关法律、法规、规范性文件及《公司章程》《监事会 议事规则》等的规定，会议召开程序合法有效。 二、监事会会议审议情况 经与会监事认真讨论，审议并通过如下事项： 的议案" 经与会监事审议，一致通过"关于赛诺医疗科学技术股份有限公司 2025 年半年度 报告及其摘要的议案"。同 ...

Core Viewpoint - Sino Medical (688108) reported a significant increase in both revenue and net profit for the first half of 2025, indicating strong performance in its core business segments [1] Financial Performance - The company achieved an operating revenue of 240 million yuan, representing a year-on-year growth of 12.53% [1] - The net profit attributable to shareholders reached 13.84 million yuan, showing a remarkable year-on-year increase of 296.54% [1] - Basic earnings per share were reported at 0.03 yuan [1] Business Segment Performance - The coronary intervention business saw a revenue increase of 17.40%, primarily driven by the significant sales growth of two coronary stent products and balloon products that entered the centralized procurement scope during the reporting period [1] - The neuro-intervention business experienced a revenue growth of 6.25%, mainly due to the sales growth of newly launched products from the previous year [1]

Company Overview - Sino Medical reported a total revenue of 240 million yuan for the first half of 2025, representing a year-on-year growth of 12.53% [1] - The net profit for the same period was 13.8416 million yuan, showing a significant increase of 296.54% compared to the previous year [1] - Earnings per share were 0.03 yuan, with a return on equity of 1.58% and operating cash flow per share of 0.1261 yuan [1] - The gross profit margin stood at 63.64% [1] Business Focus - Sino Medical, established in 2007, is located in the Tianjin Development Zone and specializes in the research, production, and sales of high-end interventional medical devices [1] - The company's product pipeline includes key areas of interventional treatment such as cardiovascular, cerebrovascular, and structural heart diseases [1] - The core product is the BuMA biodegradable drug-coated coronary stent system, which is designed and developed in-house and holds international intellectual property rights [1] Investment and Intellectual Property - Sino Medical has made investments in 7 companies and participated in 363 bidding projects [1] - The company holds 39 trademark registrations and 105 patents, along with 60 administrative licenses [1]

从8月22日公开信息显示，赛诺医疗截至2025年6月30日公司股东户数为1.11万户，较上期（2025年3月31日）增加46户，增幅 为0.42%，变化不大。 从数据对比来看，赛诺医疗户均持股数从上期3.74万股上升值本期3.75万股,户均持股市值从上期39.91万元上升至本期42.09万 元。上述区间，赛诺医疗股价累计上涨263.66%。 统计日期股东户数户均持股数（万股）户均持股市值（万元） 2025/06/30110903.7542.092025/03/31110443.7439.912024/09/30104023.9743.332024/06/30108343.8234.122023/12/31107363.8247.93 来源：金融界 截至发稿，赛诺医疗报34.22元，下跌8.21%，市值142.37亿元。 最新5个统计日期，赛诺医疗股东户数变动如下： ...

经与会监事审议，一致通过"关于赛诺医疗科学技术股份有限公司 2025 年半年度 报告及其摘要的议案"。同意公司编制的《2025 年半年度报告》及其摘要。 一、监事会会议召开情况 赛诺医疗科学技术股份有限公司（以下简称"赛诺医疗"或"公司"）第三届监 事会第六次会议通知于 2025 年 8 月 8 日以书面送达等方式通知各位监事。会议于 2025 年 8 月 21 日在北京市海淀区高梁桥斜街 59 号中坤大厦 7 层公司会议室以现场和通讯 相结合的方式召开。本次会议应出席监事 3 人，实际出席监事 3 人。本次会议由监事 会主席于长春先生召集并主持，公司部分高管列席了本次会议。本次会议的召开符合 《中华人民共和国公司法》等有关法律、法规、规范性文件及《公司章程》《监事会 议事规则》等的规定，会议召开程序合法有效。 二、监事会会议审议情况 经与会监事认真讨论，审议并通过如下事项： 1、审议通过"关于赛诺医疗科学技术股份有限公司 2025 年半年度报告及其摘要 的议案" 证券代码：688108 证券简称：赛诺医疗 公告编号：2025-037 赛诺医疗科学技术股份有限公司 关于第三届监事会第三次会议决议的公告 本公司 ...

证券代码：688108 证券简称：赛诺医疗 公告编号：2025-036 赛诺医疗科学技术股份有限公司 具体内容详见公司于同日披露在上海证券交易所网站（www.sse.com.cn）的《赛 诺医疗科学技术股份有限公司 2025 年半年度报告》及《赛诺医疗科学技术股份有限 公司 2025 年半年度报告摘要》。 关于第三届董事会第六次会议决议的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 赛诺医疗科学技术股份有限公司（以下简称"赛诺医疗"或"公司"）第三届董 事会第六次会议通知于 2025 年 8 月 8 日以书面等方式送达各位董事和监事。会议于 2025 年 8 月 21 日以现场和通讯相结合的方式在北京市海淀区高梁桥斜街 59 号中坤大 厦 7 层公司会议室召开。本次会议应出席董事 9 人，实际出席董事 9 人。本次会议由 为定期会议，由董事长孙箭华先生召集并主持，公司监事、部分高管列席了本次会议。 本次会议的召开符合《中华人民共和国公司法》等有关法律、法规、规范性文件及《公 司章程》《董事会 ...

格隆汇8月21日丨赛诺医疗(688108.SH)公布2025年半年度报告，报告期实现营业收入2.4亿元，同比增长 12.53%；归属于上市公司股东的净利润1384.16万元，同比增长296.54%；归属于上市公司股东的扣除非 经常性损益的净利润797.77万元；基本每股收益0.03元。 ...